-A new Juniper Research study has found that the global number of roaming subscribers using 5G services will increase from 4.5 million in 2021 to 210 million in 2026. As the international travel industry recovers from the COVID-19 pandemic, it recommends that operators must now focus on increasing 5G roaming support to accommodate the future rise in demand for data when roaming over 5G networks.
At the end of the summer of 2018, contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) were continuing the trend of acquisitions and biopharmaceutical services expansions.
Contract manufacturer Catalent touted the early success of its new Biologic and Specialty Drug Delivery unit on a Tuesday earnings presentation, which helped the company achieve 19% revenue growth for its 2018 fiscal year that ended June 30.
Juniper Pharmaceuticals will become a wholly owned subsidiary of Catalent Pharma Solutions today, says the CDMO.
In another sign of consolidation in the outsourcing industry — following Catalent’s acquisition of Juniper just days ago — API manufacturer Cambrex announced its latest $425 million deal to snap up Halo Pharma, which would add to both its product development and manufacturing capacities.
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, Inc. (NASDAQ: JNPR), including its Nottingham, U.K.-based Juniper Pharma Services division. When combined with Catalent’s existing industry-leading drug development and manufacturing capabilities in the U.S. and Europe, the acquisition of Juniper will expand and strengthen Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing, and will complement its integrated global clinical and commercial supply network.
The biopharma contract developer and manufacturer Catalent $CTLT has swooped in to buy out Juniper Pharmaceuticals $JNP for $133 million, adding their services with an eye to amping up its early drug development offerings in the UK.
BOSTON, March 21, 2018 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a diversified healthcare company with core businesses of its CRINONE® (progesterone gel) franchise and fee-for-service pharmaceutical development and manufacturing business JPS, today announced the appointment of Richard Messina to the Company's Board of Directors.
Juniper Pharmaceuticals (Nasdaq: JNP), a diversified healthcare company focused on women's health, today announced the extension of its supply agreement for CRINONE® (progesterone gel) with an affiliate of Merck KGaA, Darmstadt, Germany. The amended agreement extends the supply term an additional 4.5 years and at least through to December 31, 2024. The current term was due to expire in May 2020. Merck KGaA, Darmstadt, Germany has marketing rights worldwide except the United States, where CRINONE® is marketed by Allergan plc.